Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report
Published: Jun 2021 | Pages: 127 | SKU: IRTNTR70632 |
Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report
This pipeline analysis report provides detailed insights into the clinical trials landscape of stem cell therapy for diabetes and related conditions, including molecules at the pre-clinical and discovery stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline stem cell therapies for diabetes and related conditions. A few of the key players are Anterogen Co. Ltd., Caladrius Biosciences Inc., ViaCyte Inc., Vertex Pharmaceuticals Inc, among others.
Overview of the stem cell therapy for diabetes and related conditions
Diabetes is a chronic condition associated with high sugar (glucose) levels in the blood, which is owing to the defect in insulin secretion. The prevalence of both type 1 (insulin-dependent diabetes mellitus or juvenile onset) and type 2 (non-insulin-dependent diabetes mellitus or adult-onset diabetes) is increasing globally. However, type 2 diabetes, is the more common type. According to the Centers for Disease Control and Prevention (CDC), in 2018, 34.2 million people belonging to all age groups, or 10.5% of the US population, had diabetes. Out of this, 26.9 million people, or 8.2% of the US population, had diabetes that had been diagnosed. According to the IDF Diabetes Atlas, an estimated 59 million adults (20-79 years) were living with diabetes in the IDF Europe Region in 2019. On the other hand, other Asian countries, such as Japan, Sri Lanka, Indonesia, Thailand, and Vietnam, have also witnessed a significant increase in the prevalence of diabetes in the past decade.
According to this pipeline analysis report, most of the molecules in the pipeline are being developed for monotherapy and combination therapy. Over 54% of the drug development is in the pre-clinical stage.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of stem cell therapy for diabetes and related conditions. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the stem cell therapy molecules for diabetes discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Anterogen Co. Ltd.
- AgeX Therapeutics Inc.
- Caladrius Biosciences Inc.
Therapeutic assessment of the stem cell therapy for diabetes and related conditions route of administration
- Intravenous
- Intramuscular
- Topical
- Others
The intravenous route of administration (ROA) involves drug delivery through the subcutis. In the current pipeline, four molecules are administered through this route. On the other hand, intramuscular drug delivery has just one molecule currently being administered.
Therapeutic assessment of the stem cell therapy for diabetes and related conditions by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently being developed as stem cell therapy for diabetes and related conditions are as monotherapy drugs. About 20 monotherapy molecules are under development. In addition to the active molecules, there are also a number of pipeline products that have been either discontinued from development or are currently dormant.
Key questions answered in the report include
- What are the stem cell therapy molecules in the various development stages for diabetes and related conditions?
- What are the companies that are currently involved in the development of stem cell therapy for diabetes and related conditions?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirements. Get in touch
PART 01: Executive summary
PART 02: Scope
- Scope of the report
PART 03: Disease overview
- Introduction
PART 04: Regulatory framework
PART 05: Drug development landscape
- Drugs under development
PART 06: Drug development strategies
- Therapies employed
- RoA
- Therapeutic modalities
- Targets for drug development
- Mechanism of action (MoA)
PART 07: Recruitment strategies
- Geographical coverage
- Recruitment status
- Gender of participants
- Age structure
- Recruitment volume
PART 08: Key companies
- Overview
- Type of players
PART 09: AgeX Therapeutics Inc.
- Overview
PART 10: Anterogen Co. Ltd.
- Overview
PART 11: Caladrius Biosciences Inc.
- Overview
PART 12: Evotec
- Overview
PART 13: Fresenius Medical Care AG & Co. KGaA
- Overview
PART 14: Kadimastem Ltd.
- Overview
PART 15: Mesoblast Ltd.
- Overview
PART 16: NextCell Pharma AB
- Overview
PART 17: Ossium Health
- Overview
PART 18: PanCryos
- Overview
PART 19: ReNeuron Group plc
- Overview
PART 20: RHEACELL GmbH & Co. KG
- Overview
PART 21: Sana Biotechnology
- Overview
PART 22: Seraxis Inc.
- Overview
PART 23: Sernova Corp.
- Overview
PART 24: Sigilon Therapeutics Inc.
- Overview
PART 25: Thomas Advanced Medical LLC
- Overview
PART 26: Tianhe Stem Cell Biotechnologies Inc.
- Overview
PART 27: Vertex Pharmaceuticals Inc.
- Overview
PART 28: ViaCyte Inc.
- Overview
PART 29: XOStem Inc.
- Overview
PART 30: Dormant and Discontinued therapeutic candidates
PART 31: Appendix
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis